2011
Exome Sequencing of Head and Neck Squamous Cell Carcinoma Reveals Inactivating Mutations in NOTCH1
Agrawal N, Frederick MJ, Pickering CR, Bettegowda C, Chang K, Li RJ, Fakhry C, Xie TX, Zhang J, Wang J, Zhang N, El-Naggar AK, Jasser SA, Weinstein JN, Treviño L, Drummond JA, Muzny DM, Wu Y, Wood LD, Hruban RH, Westra WH, Koch WM, Califano JA, Gibbs RA, Sidransky D, Vogelstein B, Velculescu VE, Papadopoulos N, Wheeler DA, Kinzler KW, Myers JN. Exome Sequencing of Head and Neck Squamous Cell Carcinoma Reveals Inactivating Mutations in NOTCH1. Science 2011, 333: 1154-1157. PMID: 21798897, PMCID: PMC3162986, DOI: 10.1126/science.1206923.Peer-Reviewed Original ResearchMeSH KeywordsCarcinomaCarcinoma, Squamous CellCell Cycle ProteinsCodon, NonsenseExonsF-Box ProteinsF-Box-WD Repeat-Containing Protein 7Gene DosageGenes, p53Genes, Tumor SuppressorHead and Neck NeoplasmsHumansINDEL MutationMutationMutation, MissenseNeoplasms, Squamous CellOligonucleotide Array Sequence AnalysisOncogenesPapillomaviridaePapillomavirus InfectionsReceptor, Notch1Sequence Analysis, DNASmokingSquamous Cell Carcinoma of Head and NeckUbiquitin-Protein LigasesConceptsNeck squamous cell carcinomaSquamous cell carcinomaCell carcinomaHuman papillomavirusHPV-positive tumorsWhole-exome sequencingMore mutationsPrimary tumorCommon cancerMultiple tumorsTobacco useTumor typesTumorsTumor suppressor geneExome sequencingGene copy number analysisNotch1Copy number analysisPatientsCarcinomaInactivating mutationCancerSuppressor geneMutationsGenetic originPhosphoproteomic Analysis of Signaling Pathways in Head and Neck Squamous Cell Carcinoma Patient Samples
Frederick MJ, VanMeter AJ, Gadhikar MA, Henderson YC, Yao H, Pickering CC, Williams MD, El-Naggar AK, Sandulache V, Tarco E, Myers JN, Clayman GL, Liotta LA, Petricoin EF, Calvert VS, Fodale V, Wang J, Weber RS. Phosphoproteomic Analysis of Signaling Pathways in Head and Neck Squamous Cell Carcinoma Patient Samples. American Journal Of Pathology 2011, 178: 548-571. PMID: 21281788, PMCID: PMC3070553, DOI: 10.1016/j.ajpath.2010.10.044.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorBlotting, WesternCarcinoma, Squamous CellCell Line, TumorCluster AnalysisFemaleHead and Neck NeoplasmsHumansImmunohistochemistryMaleMucous MembraneNeoplasm ProteinsPhosphoproteinsPhosphorylationProtein Array AnalysisProtein Kinase CProteomicsReproducibility of ResultsSignal TransductionConceptsReverse-phase protein microarrayNeck squamous cell carcinomaSquamous cell carcinomaEukaryotic translation initiation factor 4ETranslation initiation factor 4ECell carcinomaInitiation factor 4ESmall molecule inhibitorsSerine 345Phosphoproteomic analysisChk-2Protein kinaseSignaling pathwaysElevated analytesPatient-specific differencesLung cancerBiopsy specimensPromising new strategyProtein microarraysTumor typesTheranostic testsEnd pointPatient samplesTumorsPersonalized therapy
2001
Is p53 Haploinsufficient for Tumor Suppression? Implications for the p53+/- Mouse Model in Carcinogenicity Testing
Venkatachalam S, Tyner S, Pickering C, Boley S, Recio L, French J, Donehower L. Is p53 Haploinsufficient for Tumor Suppression? Implications for the p53+/- Mouse Model in Carcinogenicity Testing. Toxicologic Pathology 2001, 29: 147-154. PMID: 11695551, DOI: 10.1080/019262301753178555.Peer-Reviewed Original ResearchConceptsEnhanced tumor susceptibilityWild-type p53 alleleP53-deficient miceMouse modelP53 alleleP53 dosageTumor susceptibilityTransgenic mouse modelWild-type littermatesDifferent tumor typesP53 tumor suppressor geneTumor suppressionP53 LOHTumor typesTumorsTumor suppressor geneMiceP53 lossHaploinsufficient tumor suppressorCarcinogenicity testingPreliminary dataOncogenic lesionsCancer formationMechanisms of genotoxicityTumor suppressor